
Three platform-technology deals paired Nanexa, Earendil Labs, and Atavistik Bio with Novo Nordisk, Genentech, and Roche to advance next-generation metabolic and oncology medicines.
Nicholas Jacobus is a content associate for Pharmaceutical Executive and can be reached at njacobus@mjhlifesciences.com.

Three platform-technology deals paired Nanexa, Earendil Labs, and Atavistik Bio with Novo Nordisk, Genentech, and Roche to advance next-generation metabolic and oncology medicines.

InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes, and Jen Lamppa talks fixing clinical trial patient enrollment with real-world data.

Eli Lilly is set to pay InnoCare Pharma up to $3.35 billion to discover and develop compounds against upwards of five undisclosed targets.

FDA approves Onswik, Eli Lilly's once-weekly basal insulin for adults with type 2 diabetes.

EVERSANA's Jen Norton talks about how AI is reshaping market access strategy, a new analysis from MIT and Harvard Business School names clinical data harmonization as the real barrier to enterprise AI adoption in life sciences, and Novo Nordisk's CEO says he's open to a direct NYSE listing.

Novo Nordisk CEO Mike Doustdar says he's open to a direct NYSE listing that would replace the company's ADR structure.

Nine major European drugmakers warn the region risks losing pharma investment, Novartis licenses a preclinical radioligand therapy asset from BoomRay Pharmaceuticals, and Rafaat Rahmani argues that the costliest competitive intelligence failure is missing the moment a strategic assumption goes wrong.

Chairs of Europe's largest drugmakers urge the EU to boost health spending, speed up clinical trials, and strengthen IP protections before falling further behind the US and China.

Novartis has agreed to pay BoomRay up to $900 million for exclusive global rights to an undisclosed preclinical radioligand therapy asset.

AbbVie partners with Iambic on AI-driven drug discovery as Telix Pharmaceuticals moves to acquire ITM Isotope Technologies in a multibillion-dollar radiopharmaceutical merger, Novo Nordisk's CagriSema outperforms Eli Lilly's tirzepatide in a head-to-head diabetes trial, and Jen Lamppa of Inovalon discusses how real-time clinical data is reshaping trial recruitment.

AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.

Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.

FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.

Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.

FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.

Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.

Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.

FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon Medical strike major deals and mergers with Orbis Medicines, Dualitas Therapeutics, and North Immunology, and Thani Jambulingam of Saint Joseph's University examines the fight to control the GLP-1 patient journey.

Orbis Medicines strikes a partnership with Novo, Dualitas Therapeutics enters collaboration with Roche, and Aethlon Medical has agreed to merge with North Immunology.

FDA has approved Bayer's Kerendia to reduce disease progression risk in adults with chronic kidney disease associated with type 1 diabetes.

Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance, touches on what he sees as the most realistic path to making MFN pricing permanent.

Novo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, and IQVIA's Phil Ford makes the case for reimagining medical content as a loop rather than a pipeline.

Novo partners with Anthropic to deploy Claude for targeted drug discovery workflows and AI-driven software development.

Sling Therapeutics closes a $123 million Series C to advance linsitinib, while Circle Pharma raises an oversubscribed $92.5 million Series E to move CID-165, into clinical development for ER-positive breast cancer.

Joe Cunningham argues that the most-favored-nation drug pricing agreements carry no legislative weight and discusses what the program actually locks in.

GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why pharma marketing now has to write for both people and AI, and Dr. Elena Christofides explains why cortisol dysregulation may be the hidden reason some diabetes patients fail to respond to incretin therapies.

GSK agrees to acquire a trispecific T cell engager for multiple myeloma from Chimagen Biosciences, while Sanofi is offloading 20 mature medicines and three manufacturing sites to Cheplapharm.

Cellectis pivots from CAR-T to in vivo gene editing, Novo Nordisk rebrands as "Novo" to sharpen its competitive edge in obesity and diabetes care, and Wendy Short Bartie of Bristol Myers Squibb makes the case for reputation as a strategic currency.

Cellectis is pivoting from allogeneic CAR-T development to become an in vivo gene editing company, discontinuing its lasme-cel and eti-cel programs.

Novo Nordisk rebrands as "Novo" under it's "Lasting health starts now" tagline, pairing both with a new cultural framework called "The Novo Way."